Novel P2y12(小说 P2y12)研究综述
Novel P2y12 小说 P2y12 - This meta-analysis investigated whether ticagrelor, a novel P2Y12 inhibitor, was superior to clopidogrel and prasugrel in efficacy and safety for DM patients undergoing PCI. [1] Therefore, the PD interaction liability of the novel P2Y12 receptor antagonist selatogrel with irreversible (i. [2] For over a decade novel P2Y12 inhibitors, which have increased specificity, potency and efficacy have been available, prompting studies which have tested whether these newer agents can be used in aspirin-free anti-platelet regimens to augment clinical benefits in patients post-PCI. [3] Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes. [4] BACKGROUND AND PURPOSE: Ticagrelor is a novel P2Y12 antagonist, and little is known about its efficacy and safety in the endovascular treatment of aneurysms. [5] Our preliminary data suggest that morphine may have no impact on mortality in STEMI patients treated with primary PCI and medical therapy according to the current guidelines including novel P2Y12 antagonists. [6] In patients with an acute coronary syndrome undergoing percutaneous coronary intervention, novel P2Y12 receptor inhibitors, prasugrel and ticagrelor, are proposed as “first-line” antiplatelet agents in the absence of contraindications and up to a year from the index event. [7] Prasugrel, a novel P2Y12 receptor antagonist, has been shown to be more effective than clopidogrel for preventing cardiovascular events in patients with acute coronary syndromes undergoing percutaneous coronary intervention. [8] We aimed to investigate the therapeutic strategies, the use of novel P2Y12 inhibitors, and the prognostic implication of anemia in a "real world" cohort of ACS patients. [9] Aims To study the pharmacodynamics and pharmacokinetics of selatogrel, a novel P2Y12 receptor antagonist for subcutaneous administration, in patients with chronic coronary syndromes (CCS). [10] We aimed to investigate differences in prognosis of acute coronary syndrome patients with and without CKD, focusing on the use of novel P2Y12 receptor inhibitors. [11] 3 h) and was not mitigated by the novel P2Y12 inhibitors. [12] We studied PPI prescription in ACS patients in the era of novel P2Y12 inhibitors and assessed the association between PPI use and clinical outcomes. [13]这项荟萃分析调查了新型 P2Y12 抑制剂替格瑞洛对接受 PCI 的 DM 患者的疗效和安全性是否优于氯吡格雷和普拉格雷。 [1] 因此，新型 P2Y12 受体拮抗剂 selatogrel 与不可逆 (i. [2] 十多年来，具有更高特异性、效力和疗效的新型 P2Y12 抑制剂已经上市，促使研究测试这些新型药物是否可用于无阿司匹林的抗血小板方案以增加 PCI 后患者的临床益处。 [3] 慢性冠状动脉综合征患者单剂量皮下给药 selatogrel（一种新型 P2Y12 受体拮抗剂）的药效学、药代动力学和安全性。 [4] 背景与目的：替格瑞洛是一种新型的 P2Y12 拮抗剂，对其在动脉瘤血管内治疗中的疗效和安全性知之甚少。 [5] 我们的初步数据表明，根据包括新型 P2Y12 拮抗剂在内的现行指南，吗啡可能对接受直接 PCI 和药物治疗的 STEMI 患者的死亡率没有影响。 [6] 在接受经皮冠状动脉介入治疗的急性冠状动脉综合征患者中，新的 P2Y12 受体抑制剂普拉格雷和替格瑞洛被建议作为“一线”抗血小板药物，在没有禁忌症的情况下，并且距离指标事件最多一年。 [7] 普拉格雷是一种新型 P2Y12 受体拮抗剂，已被证明在预防接受经皮冠状动脉介入治疗的急性冠状动脉综合征患者的心血管事件方面比氯吡格雷更有效。 [8] 我们旨在调查治疗策略、新型 P2Y12 抑制剂的使用以及贫血在“现实世界”ACS 患者队列中的预后意义。 [9] 目的 研究用于皮下给药的新型 P2Y12 受体拮抗剂 selatogrel 在慢性冠状动脉综合征 (CCS) 患者中的药效学和药代动力学。 [10] 我们旨在调查患有和未患有 CKD 的急性冠状动脉综合征患者的预后差异，重点关注新型 P2Y12 受体抑制剂的使用。 [11] 3 h）并且没有被新型P2Y12抑制剂减轻。 [12] 我们研究了新型 P2Y12 抑制剂时代 ACS 患者的 PPI 处方，并评估了 PPI 使用与临床结果之间的关联。 [13]
novel p2y12 receptor 新型 P2y12 受体
Therefore, the PD interaction liability of the novel P2Y12 receptor antagonist selatogrel with irreversible (i. [1] Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes. [2] In patients with an acute coronary syndrome undergoing percutaneous coronary intervention, novel P2Y12 receptor inhibitors, prasugrel and ticagrelor, are proposed as “first-line” antiplatelet agents in the absence of contraindications and up to a year from the index event. [3] Prasugrel, a novel P2Y12 receptor antagonist, has been shown to be more effective than clopidogrel for preventing cardiovascular events in patients with acute coronary syndromes undergoing percutaneous coronary intervention. [4] Aims To study the pharmacodynamics and pharmacokinetics of selatogrel, a novel P2Y12 receptor antagonist for subcutaneous administration, in patients with chronic coronary syndromes (CCS). [5] We aimed to investigate differences in prognosis of acute coronary syndrome patients with and without CKD, focusing on the use of novel P2Y12 receptor inhibitors. [6]因此，新型 P2Y12 受体拮抗剂 selatogrel 与不可逆 (i. [1] 慢性冠状动脉综合征患者单剂量皮下给药 selatogrel（一种新型 P2Y12 受体拮抗剂）的药效学、药代动力学和安全性。 [2] 在接受经皮冠状动脉介入治疗的急性冠状动脉综合征患者中，新的 P2Y12 受体抑制剂普拉格雷和替格瑞洛被建议作为“一线”抗血小板药物，在没有禁忌症的情况下，并且距离指标事件最多一年。 [3] 普拉格雷是一种新型 P2Y12 受体拮抗剂，已被证明在预防接受经皮冠状动脉介入治疗的急性冠状动脉综合征患者的心血管事件方面比氯吡格雷更有效。 [4] 目的 研究用于皮下给药的新型 P2Y12 受体拮抗剂 selatogrel 在慢性冠状动脉综合征 (CCS) 患者中的药效学和药代动力学。 [5] 我们旨在调查患有和未患有 CKD 的急性冠状动脉综合征患者的预后差异，重点关注新型 P2Y12 受体抑制剂的使用。 [6]
novel p2y12 inhibitor 新型 P2y12 抑制剂
This meta-analysis investigated whether ticagrelor, a novel P2Y12 inhibitor, was superior to clopidogrel and prasugrel in efficacy and safety for DM patients undergoing PCI. [1] For over a decade novel P2Y12 inhibitors, which have increased specificity, potency and efficacy have been available, prompting studies which have tested whether these newer agents can be used in aspirin-free anti-platelet regimens to augment clinical benefits in patients post-PCI. [2] We aimed to investigate the therapeutic strategies, the use of novel P2Y12 inhibitors, and the prognostic implication of anemia in a "real world" cohort of ACS patients. [3] 3 h) and was not mitigated by the novel P2Y12 inhibitors. [4] We studied PPI prescription in ACS patients in the era of novel P2Y12 inhibitors and assessed the association between PPI use and clinical outcomes. [5]这项荟萃分析调查了新型 P2Y12 抑制剂替格瑞洛对接受 PCI 的 DM 患者的疗效和安全性是否优于氯吡格雷和普拉格雷。 [1] 十多年来，具有更高特异性、效力和疗效的新型 P2Y12 抑制剂已经上市，促使研究测试这些新型药物是否可用于无阿司匹林的抗血小板方案以增加 PCI 后患者的临床益处。 [2] 我们旨在调查治疗策略、新型 P2Y12 抑制剂的使用以及贫血在“现实世界”ACS 患者队列中的预后意义。 [3] 3 h）并且没有被新型P2Y12抑制剂减轻。 [4] 我们研究了新型 P2Y12 抑制剂时代 ACS 患者的 PPI 处方，并评估了 PPI 使用与临床结果之间的关联。 [5]
novel p2y12 antagonist 小说 P2y12 拮抗剂
BACKGROUND AND PURPOSE: Ticagrelor is a novel P2Y12 antagonist, and little is known about its efficacy and safety in the endovascular treatment of aneurysms. [1] Our preliminary data suggest that morphine may have no impact on mortality in STEMI patients treated with primary PCI and medical therapy according to the current guidelines including novel P2Y12 antagonists. [2]背景与目的：替格瑞洛是一种新型的 P2Y12 拮抗剂，对其在动脉瘤血管内治疗中的疗效和安全性知之甚少。 [1] 我们的初步数据表明，根据包括新型 P2Y12 拮抗剂在内的现行指南，吗啡可能对接受直接 PCI 和药物治疗的 STEMI 患者的死亡率没有影响。 [2]